JP Patent

JP6276756B2 — 1,1−ジメチルエチル[(1s)−1−{[(2s,4r)−4−(7−クロロ−4メトキシイソキノリン−1−イルオキシ)−2−({(1r,2s)−1−[(シクロプロピルスルホニル)カルバモイル]−2−エテニルシクロプロピル}カルバモイル)ピロリジン−1−イル]カルボニル}−2,2−ジメチルプロピル]カルバメートの可溶化カプセル製剤

Assigned to Bristol Myers Squibb Holdings Ireland ULC · Expires 2018-02-07 · 8y expired

What this patent protects

Patent listed against Bumex.

Drugs covered by this patent

Patent Metadata

Patent number
JP6276756B2
Jurisdiction
JP
Classification
Expires
2018-02-07
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Holdings Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.